The Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica’s certified laboratory partner that the test will be reviewed on an individual,...
— Represents Biomerica’s First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an...
IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today...
First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe. Strategic Account:...
UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic...
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent...
Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare Market Simple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes ...
Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA),...
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure. The $300 rate will apply to claims approved and paid...
Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease,...